Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 245-249, 2014.
Artículo
en Chino
| WPRIM
| ID: wpr-349727
ABSTRACT
Survival and progression of patients with mature B-cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin's lymphoma, depend on signals from the B -cell receptor, and Bruton's tyrosine kinase(BTK) is a critical signaling kinase in this pathway. Ibrutinib is a novel and selective inhibitor of BTK, inactivating the kinase irreversibly. It has shown exciting results in early clinical trials. In this review, the application and molecular mechanism of Ibrutinib in the treatment of B-cell malignancies are discussed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pirazoles
/
Pirimidinas
/
Linfoma no Hodgkin
/
Proteínas Tirosina Quinasas
/
Leucemia de Células B
/
Leucemia Linfocítica Crónica de Células B
/
Usos Terapéuticos
/
Quimioterapia
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS